Keryx Biopharmaceuticals Inc. (KERX) Stock Price Down 1.1%
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) shares fell 1.1% on Friday . The stock traded as low as $7.34 and last traded at $7.43, with a volume of 407,661 shares. The stock had previously closed at $7.51.
Several brokerages have commented on KERX. Morgan Stanley restated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, April 30th. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Wednesday, July 13th. Cowen and Company restated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, April 30th. FBR & Co restated a “buy” rating and set a $13.00 target price on shares of Keryx Biopharmaceuticals in a report on Friday, April 29th. Finally, Maxim Group restated a “buy” rating and set a $7.00 target price (up from $5.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, March 29th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $8.84.
The stock’s market capitalization is $785.18 million. The firm’s 50-day moving average is $6.54 and its 200-day moving average is $5.04.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.13. The business earned $6.80 million during the quarter, compared to analysts’ expectations of $6.63 million. During the same quarter last year, the firm earned ($0.28) EPS. The business’s quarterly revenue was up 466.7% on a year-over-year basis. Equities analysts anticipate that Keryx Biopharmaceuticals Inc. will post ($0.97) EPS for the current fiscal year.
An institutional investor recently bought a new position in Keryx Biopharmaceuticals stock. Royce & Associates LLC purchased a new position in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned approximately 0.32% of Keryx Biopharmaceuticals at the end of the most recent reporting period.
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.